Prevalence of Hyperuricemia and Associated Factors Among Type 2 Diabetic Patients in Jordan

Mousa Abujbara; Huda M Al Hourani; Reem Ibrahim Al-Raoush; Yousef S Khader; Kamel Ajlouni

doi:10.2147/IJGM.S376857

Prevalence of Hyperuricemia and Associated Factors Among Type 2 Diabetic Patients in Jordan

Int J Gen Med. 2022 Aug 16:15:6611-6619. doi: 10.2147/IJGM.S376857. eCollection 2022.

Authors

Mousa Abujbara¹, Huda M Al Hourani², Reem Ibrahim Al-Raoush¹, Yousef S Khader³, Kamel Ajlouni¹

Affiliations

¹ The National Centre (Institute) for Diabetes, Endocrinology and Genetics, The University of Jordan, Amman, Jordan.
² Department of Clinical Nutrition and Dietetics, Faculty of Applied Health Sciences, The Hashemite University, Zarqa, Jordan.
³ Jordan University of Science and Technology (JUST), Irbid, Jordan.

Abstract

Background: Previous studies showed variable estimate of the prevalence of hyperuricemia in patients with type 2 diabetes mellitus (T2DM). The prevalence of hyperuricemia and associated risk factors in Jordanian patients with T2DM is largely unknown. Therefore, this study aimed to determine the prevalence of hyperuricemia and its associated factors in Jordanian patients with T2DM.

Methods: A cross-sectional study was conducted on 655 patients with T2DM. A structured questionnaire was used to collect socio-demographic data. In addition, records of the study subjects were reviewed to obtain other clinical data. Weight, height, and waist circumference were measured, and body mass index was calculated. Lipid profile, serum uric acid and glycated haemoglobin were analysed. The study was conducted in accordance with the Declaration of Helsinki. An informed written consent was obtained from each participant. The confidentiality of the information was assured and only used for scientific purposes.

Results: Overall, the prevalence of hyperuricemia was 28.1%. Female gender (OR: 2.37; 95%, CI: 1.63-3.45), intake of angiotensin-converting enzyme (ACE) and angiotensin-II receptor blockers (ARBs) (OR: 1.68; 95%, CI: 1.12-2.50), intake of β-blockers (OR: 2.20; 95%, CI: 1.51-3.22), increased waist circumference (OR: 3.17; 95%, CI: 1.39-7.22) and family history of hyperuricemia (OR: 2.56; 95%, CI: 1.57-4.16) were associated with increased odds of hyperuricemia.

Conclusion: Hyperuricemia was high among type 2 diabetic patients, and screening test will be useful for those patients.

Keywords: diabetes mellitus; hyperuricemia; uric acid.